

[Techcyte, Aiforia collaborate to advance AI-powered DP](#)

written by CAP TODAY
June 10, 2025

June 2025—Techcyte and Aiforia announced a strategic partnership to accelerate the adoption of AI-driven workflows in anatomic pathology laboratories. The partnership brings together Techcyte’s Fusion digital pathology platform and Aiforia’s AI-powered diagnostic algorithms, beginning with the Aiforia breast cancer suite. The companies say the partnership will continue to drive innovation in digital pathology, cancer diagnostics, and more with an expanding portfolio of AI applications.



©2026 CAP TODAY, all rights reserved.

[More than 100,000 patients tested with MeMed BV](#)

written by CAP TODAY
June 10, 2025

June 9, 2025—MeMed announced that more than 100,000 patients have been tested with MeMed BV, the company’s flagship diagnostic that distinguishes between bacterial and viral infections based on the body’s immune response.



©2026 CAP TODAY, all rights reserved.

CAP, Joint Commission agree on advance notification policy

written by CAP TODAY
June 10, 2025

June 5, 2025—The College of American Pathologists and the Joint Commission have reached an agreement permitting advance notification of laboratory inspections at Joint Commission-accredited hospitals.



©2026 CAP TODAY, all rights reserved.

FDA approves Randox ConcizuTrace ELISA CDx

written by CAP TODAY
June 10, 2025

June 4, 2025—The Food and Drug Administration has approved the de novo application for Randox Laboratories' first companion diagnostic, the Randox ConcizuTrace ELISA.



©2026 CAP TODAY, all rights reserved.

Pillar raises \$34.5 million in funding

written by CAP TODAY
June 10, 2025

May 27, 2025—Pillar Biosciences announced it has finalized \$34.5 million in funding, including a strategic investment from Illumina and structured financing from Soleus Capital and investments from existing investors.



©2026 CAP TODAY, all rights reserved.

[BMS at USCAP 2025 - Doubly informed: Evidence and best practices for MSI-H and MMR testing in mCRC](#)

written by CAP TODAY
June 10, 2025

Discover the insights from our recent presentation with over 180 live attendees! Engage with real-time audience polling through Slido, where participants shared their current practices in colorectal cancer (CRC) diagnosis. Learn why MMR is considered the most crucial biomarker at the initial diagnosis and explore the key challenges in MSI and MMR testing, such as inadequate tissue at biopsy and community setting limitations.



©2026 CAP TODAY, all rights reserved.

[FDA clears Tribun Health digital pathology](#)

[platform](#)

written by CAP TODAY
June 10, 2025

May 21, 2025—Tribun Health announced that its flagship web-based image management system, CaloPix, has received FDA 510(k) clearance for use with the Hamamatsu NanoZoomer S360MD and Leica Aperio GT 450 DX scanners.



©2026 CAP TODAY, all rights reserved.

[FDA clears Fujirebio blood-based IVD test for Alzheimer's](#)

written by CAP TODAY
June 10, 2025

May 19, 2025—Fujirebio announced that the FDA has granted 510(k) clearance for its Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test.



©2026 CAP TODAY, all rights reserved.

[Taking on low, ultralow HER2 breast cancer](#)

written by CAP TODAY
June 10, 2025

May 2025—Since the hunt began to identify low levels of HER2 in metastatic breast cancers, the action has revealed itself like the plot of a Henry James novel: Nothing much happens. Also, a lot happens. And each narrative thread is conveyed in hard-to-parse language. The goal has been to qualify patients for the antibody-drug conjugate trastuzumab deruxtecan (T-DXd), which was shown in the Destiny-Breast04 trial to significantly improve survival in so-called HER2-low cases. Immunohistochemistry assays were designed to identify strongly positive cases, however, and thus not useful for those at the 0 and 1+ end of the spectrum. Now, several years after the presentation of the D-B04 results at the ASCO 2022 annual meeting, which launched the low-end ship, pathologists and oncologists are adjusting to the implications of the most recent Destiny trial, D-B06. In late January, the FDA approved the drug Enhertu for HER2-low or HER2-ultralow cases, as well as the Ventana Pathway HER2 (4B5) companion diagnostic for assessing these lower levels of HER2 in patients with metastatic breast cancer.



©2026 CAP TODAY, all rights reserved.

[Misses, hits in urine drug test interpretation](#)

written by CAP TODAY
June 10, 2025

May 2025—When a physician or health care professional isn't sure how to interpret a urine drug test result, Christine Snozek, PhD, codirector of clinical chemistry at Mayo Clinic in Arizona, always hopes they'll call the laboratory for help—especially if the alternative is paging Dr. Google.



©2026 CAP TODAY, all rights reserved.